Adrenal incidentaloma: A diagnostic challenge

Hormones

Volumn 8, Issue 3, 2009, Pages 163-184

  Anagnostis, Panagiotis ^a   Karagiannis, Asterios ^a   Tziomalos, Konstantinos ^b   Kakafika, Anna I ^a   Athyros, Vasilios G ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adrenal mass; Aldosteronoma; Cushing's syndrome; Incidentaloma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPLERENONE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GOSSYPOL; INHIBITOR OF APOPTOSIS PROTEIN 1; MELPHALAN; MITOTANE; OCTREOTIDE; PENTETATE INDIUM IN 111; PROTEIN TYROSINE KINASE INHIBITOR; SPIRONOLACTONE; SURAMIN; TRACER; TRIAMTERENE; UNINDEXED DRUG; VINCRISTINE;

ADENOMA; ADRENAL BIOPSY; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CYST; ADRENAL INCIDENTALOMA; ADRENAL MEDULLA TUMOR; ADRENAL SCINTISCANNING; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ANGIOMYOLIPOMA; ASPIRATION BIOPSY; BENIGN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCINTISCANNING; CANCER SCREENING; CANCER SURGERY; CATECHOLAMINE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ERECTILE DYSFUNCTION; FOLLOW UP; FUNCTIONAL ASSESSMENT; GANGLIONEUROMA; GRANULOMA; GYNECOMASTIA; HEMANGIOMA; HIGH RISK POPULATION; HORMONE DETERMINATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYDROCORTISONE URINE LEVEL; HYPERALDOSTERONISM; HYPERCORTISOLISM; HYPERTENSION; LAPAROSCOPIC SURGERY; LIBIDO DISORDER; LIPOMA; LYMPHOMA; MALIGNANT TRANSFORMATION; METASTASIS; MONOTHERAPY; MYELOLIPOMA; NEUROBLASTOMA; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY HYPERALDOSTERONISM; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PSEUDOCYST; REVIEW; RISK ASSESSMENT; SALIVA LEVEL; SENSITIVITY AND SPECIFICITY; SEX HORMONE DETERMINATION; TUMOR BIOPSY; TUMOR LOCALIZATION; ADRENAL TUMOR; ALGORITHM; INCIDENTAL FINDING; NEEDLE BIOPSY;

ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL ADENOMA; ALGORITHMS; BIOPSY, FINE-NEEDLE; CUSHING SYNDROME; HUMANS; INCIDENTAL FINDINGS; MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70349245394     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1233     Document Type: Review

References (181)

1. Grumbach MM, Biller BM, Braunstein GD, et al, 2003 Management of the clinically inapperent adrenal mass ("incidentaloma"). Ann Intern Med 138: 424-429. (Pubitemid 36262654)
2. Young WF Jr, 2007 Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356: 601-610.
3. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR, 2004 The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25: 309-340. (Pubitemid 38528713)
4. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M, 2003 Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149: 273-285.
5. Mantero F, Terzolo M, Arnaldi G, et al, 2000 A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85: 637-644.
6. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B, 1995 Incidentally discovered adrenal masses. Endocr Rev 16: 460-484.
7. Masumori N, Adachi H, Noda Y, Tsukamoto T, 1998 Detection of adrenal and retroperitoneal masses in a general health examination system. Urology 52: 572-576. (Pubitemid 28440160)
8. Belldegrun A, Hussain S, Seltzer SE, Loughlin KR, Gittes RF, Richie JP, 1986 Incidentally discovered mass of the adrenal gland. Surg Gynecol Obstet 163: 203-208. (Pubitemid 16042459)
9. Caplan RH, Strutt PJ, Wickus GG, 1994 Subclinical hormone secretion by incidentally discovered adrenal masses. Arch Surg 129: 291-296.
10. Abecassis M, McLoughlin MJ, Langer B, Kudlow JE, 1985 Serendipitous adrenal masses: prevalence, significance, and management. Am J Surg 149: 783-788. (Pubitemid 15004757)
11. Dobbie JW, 1969 Adrenocortical nodular hyperplasia: the ageing adrenal. J Pathol 99: 1-18.
12. Mendonca BB, Lucon AM, Menezes CA, et al, 1995 Clinical, hormonal and pathological findings in a comparative study of adrenocortical neoplasms in childhood and adulthood. J Urol 154: 2004-2009.
13. Latronico AC, Chrousos GP, 1997 Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab 82: 1317-1324. (Pubitemid 27200395)
14. Kasperlik-Zaluska AA, Otto M, Cichocki A, et al, 2008 Incidentally discovered adrenal tumors: a lesson from observation of 1,444 patients. Horm Metab Res 40: 338-341. (Pubitemid 351859445)
15. Reincke M, Nieke J, Krestin GP, Saeger W, Allolio B, Winkelmann W, 1992 Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome. J Clin Endocrinol Metab 75: 826-832.
16. Ross NS, 1994 Epidemiology of Cushing's syndrome and subclinical disease. Endocrinol Metab Clin North Am 23: 539-546.
17. Barzon L, Fallo F, Sonino N, Boscaro M, 2002 Development of overt Cushing's syndrome in patients with adrenal incidentaloma. Eur J Endocrinol 146: 61-66. (Pubitemid 34126421)
18. Terzolo M, Pia A, Ali A, et al, 2002 Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87: 998-1003.
19. Rossi R, Tauchmanova L, Luciano A, et al, 2000 Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 85: 1440-1448. (Pubitemid 32289484)
20. Fernandez-Real JM, Engel WR, Simo R, Salinas I, Webb SM, 1998 Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Adrenal Adenoma. Clin Endocrinol (Oxf) 49: 53-61.
21. Gopan T, Remer E, Hamrahian AH, 2006 Evaluating and managing adrenal incidentalomas. Cleve Clin J Med. 73: 561-568.
22. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT, 1983 Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58: 802-804.
23. Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F, 2007 Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 14: 935-956.
24. Bravo EL, Tagle R, 2003 Pheochromocytoma: state-of- the-art and future prospects. Endocr Rev 24: 539-553. (Pubitemid 37056243)
25. Kasperlik-Zaluska AA, Roslonowska E, Slowinska- Srzednicka J, et al, 2006 1,111 patients with adrenal incidentalomas observed at a single endocrinological center: incidence of chromaffin tumors. Ann N Y Acad Sci 1073: 38-46. (Pubitemid 44911996)
26. Page LB, Rater JW, Berberich FR, 1969 Pheochromocytoma with predominant epinephrine secretion. Am J Med 47: 648-652.
27. Kudva YC, Sawka AM, Young WF Jr, 2003 Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 88: 4533-4539.
28. Amar L, Bertherat J, Baudin E, et al, 2005 Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23: 8812-8818. (Pubitemid 46211527)
29. Bravo EL, Tarazi RC, Gifford RW, Stewart BH, 1979 Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 301: 682-686.
30. Karagiannis A, Tziomalos K, Kakafika A, et al, 2004 Paralysis as first manifestation of primary aldosteronism. Nephrol Dial Transplant 19: 2418-2419. (Pubitemid 39214148)
31. Bernini G, Moretti A, Argenio G, et al, 2002 Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endocrinol 146: 523-529. (Pubitemid 34436465)
32. Mazza A, Zamboni S, Armigliato M, et al, 2008 Endocrine arterial hypertension: diagnostic approach in clinical practice. Minerva Endocrinol 33: 127-146.
33. Nader S, Hickey RC, Sellin RV, Samaan NA, 1983 Adrenal cortical carcinoma. A study of 77 cases. Cancer 52: 707-711.
34. Sψreide JA, Brabrand K, Thoresen SO, 1992 Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 16: 663-667.
35. Wooten MD, King DK, 1993 Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72: 3145-3155.
36. Ng L, Libertino JM, 2003 Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169: 5-11. (Pubitemid 35461537)
37. Allolio B, Fassnacht M, 2006 Clinical review: Adrenocortical Carcinoma. J Clin Endocrinol Metab 91: 2027-2037. (Pubitemid 43854976)
38. Young WF Jr, 2000 Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 29: 159-185.
39. Liu YJ, Wang GM, Zhang YK, et al, 2007 The clinical characteristic of adrenal metastatic tumor. Zhonghua Wai Ke Za Zhi 45: 124-127.
40. Castillo OA, Vitagliano G, Kerkebe M, Parma P, Pinto I, Diaz M, 2007 Laparoscopic adrenalectomy for suspected metastasis of adrenal glands: our experience. Urology 69: 637-641. (Pubitemid 46574919)
41. Lam KY, Lo CY, 2002 Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol (Oxf) 56: 95-101.
42. Manassero F, Pomara G, Rappa F, Cuttano MG, Crisci A, Selli C, 2004 Adrenal myelolipoma associated with adenoma. Int J Urol 11: 326-328.
43. Tamidari H, Mishra AK, Gupta S, Agarwal A, 2006 Catecholamine secreting adrenal myelolipoma. Indian J Med Sci 60: 331-333.
44. Jung SI, Kim SO, Kang TW, Kwon DD, Park K, Ryu SB, 2007 Bilateral adrenal myelolipoma associated with hyperaldosteronism: report of a case and review of the literature. Urology 70: 1223.e11-3
45. Morimoto S, Sasaki S, Moriguchi J, et al, 1998 Unique association of pheochromocytoma with contralateral nonfunctioning adrenal cortical adenoma. Am J Hypertens 11: 117-121.
46. Timonera ER, Paiva ME, Lopes JM, Eloy C, van der Kwast T, Asa SL, 2008 Composite adenomatoid tumor and myelolipoma of adrenal gland: report of 2 cases. Arch Pathol Lab Med 132: 265-267. (Pubitemid 351213796)
47. Nigawara T, Kageyama K, Sakihara S, et al, 2008 A male case of nonclassical 21-hydroxylase deficiency first manifested in his sixties with adrenocortical incidentaloma. Endocr J 55: 291-297.
48. Jaresch S, Kornely E, Kley HK, Schlaghecke R, 1992 Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 74: 685-689.
49. Tsagarakis S, Vassiliadi D, Thalassinos N, 2006 Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest 29: 471-482.
50. Findling JW, Raff H, Aron DC, 2004 The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 89: 1222-1226.
51. Reincke M, 2000 Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am 29: 43-56.
52. Newell-Price J, Trainer P, Besser M, Grossman A, 1998 The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19: 647-672. (Pubitemid 28467716)
53. Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B, 1997 Evidence of the low dose dexamethasone suppression test to screen for Cushing's syndrome recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 34: 222-229. (Pubitemid 27236924)
54. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F, 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92: 4123-4129.
55. Yaneva M, Mosnier-Pudar H, Duguè MA, Grabar S, Fulla Y, Bertagna X, 2004 Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab 89: 3345-3351. (Pubitemid 38951902)
56. Putignano P, Toja P, Dubini A, Pecori Giraldi F, Corsello SM, Cavagnini F, 2003 Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. J Clin Endocrinol Metab 88: 4153-4157. (Pubitemid 37153715)
57. Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M, 1995 A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 43: 545-550.
58. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F, 1999 Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84: 440-448.
59. Nieman LK, Biller BM, Findling JW, et al, 2008 The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526-1540. (Pubitemid 351656485)
60. Reimondo G, Allasino B, Bovio S, Paccotti P, Angeli A, Terzolo M, 2005 Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing's syndrome. Eur J Endocrinol 153: 803-809. (Pubitemid 43020230)
61. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK, 1998 The dexamethasone suppressed corticotropin- releasing hormone stimulation test differentiates mild Cushing's disease from normal physiology. J Clin Endocrinol Metab 83: 348-352.
62. Peaston RT, Ball S, 2008 Biochemical detection of phaeochromocytoma: why are we continuing to ignore the evidence? Ann Clin Biochem 45: 6-10.
63. Gardet V, Gatta B, Simonnet G, et al, 2001 Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens 19: 1029-1035. (Pubitemid 32493635)
64. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr, 2003 A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88: 553-558. (Pubitemid 36207789)
65. Lenders JW, Pacak K, Walther MM, et al, 2002 Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287: 1427-1434.
66. D'Herbomez M, Forzy G, Bauters C, et al, 2007 An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol 156: 569-575. (Pubitemid 46796524)
67. Václavík J, Stejskal D, Lacnák B, et al, 2007 Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens 25: 1427-1431. (Pubitemid 46918830)
68. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K, 2008 Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res 40: 329-337.
69. Algeciras-Schimnich A, Preissner CM, Young WF Jr, Singh RJ, Grebe SK, 2008 Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 93: 91-95.
70. Young WF Jr, 2007 Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. Rev Endocr Metab Disord 8: 309-320.
71. Bornstein SR, Stratakis CA, Chrousos GP, 1999 Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med 130: 759-771.
72. Mulatero P, Milan A, Fallo F, et al, 2006 Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 91: 2618-2623. (Pubitemid 44024627)
73. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM, 2005 Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 16: 114-119. (Pubitemid 40432461)
74. Young WF, 2007 Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 66: 607-618.
75. Funder JW, Carey RM, Fardella C, et al, 2008 Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 3266-3281.
76. Rossi GP, Sacchetto A, Chiesura-Corona M, et al, 2001 Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 86: 1083-1090.
77. Flecchia D, Mazza E, Carlini M, et al, 1995 Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of adrenocortical tumour. Clin Endocrinol (Oxf) 42: 129-134.
78. Osella G, Terzolo M, Borretta G, et al, 1994 Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). J Clin Endocrinol Metab 79: 1532-1539.
79. Terzolo M, Ali A, Osella G, et al, 2000 The value of dehydroepiandrosterone sulfate measurement in the differentiation between benign and malignant adrenal masses. Eur J Endocrinol 142: 611-617. (Pubitemid 30399492)
80. Luton JP, Martinez M, Coste J, Bertherat J, 2000 Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center. Eur J Endocrinol 143: 111-117. (Pubitemid 30482208)
81. Lee MJ, Hahn PF, Papanicolaou N, et al, 1991 Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology 179: 415-418.
82. Angeli A, Osella G, Ali A, Terzolo M, 1997 Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 47: 279-283. (Pubitemid 27196466)
83. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ, 2001 State-of-the-art adrenal imaging. Radiographics 21: 995-1012.
84. Korobkin M, Giordano TJ, Brodeur FJ, et al, 1996 Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 200: 743-747. (Pubitemid 26282274)
85. McNicholas MM, Lee MJ, Mayo-Smith WW, Hahn PF, Boland GW, Mueller PR 1995 An imaging algorithm for the differential diagnosis of adrenal adenomas and metastases. Am J Roentgenol 165: 1453-1459.
86. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR, 1998 Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. Am J Roentgenol 171: 201-204.
87. Hamrahian AH, Ioachimescu AG, Remer EM, et al, 2005 Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 90: 871-877.
88. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K, 2007 The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14: 587-599. (Pubitemid 350074049)
89. Cyran KM, Kenney PJ, Memel DS, Yacoub I, 1996 Adrenal myelolipoma. Am J Roentgenol 166: 395-400.
90. Caoili EM, Korobkin M, Francis IR, et al, 2002 Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222: 629-633. (Pubitemid 34215205)
91. Dunnick NR, Korobkin M, 2002 Imaging of adrenal incidentalomas: current status. Am J Roentgenol 179: 559-568. (Pubitemid 34919559)
92. Thompson GB, Young WF Jr, 2003 Adrenal incidentaloma. Curr Opin Oncol 15: 84-90.
93. Lockhart ME, Smith JK, Kenney PJ, 2002 Imaging of adrenal masses. Eur J Radiol 41: 95-112.
94. Krestin GP, Freidmann G, Fishbach R, Neufang KF, Alloue B, 1991 Evaluation of adrenal masses in oncologic patients: dynamic contrast-enhanced MR vs CT. J Comput Assist Tomogr 15: 104-110.
95. Kazerooni EA, Sisson JC, Shapiro B, et al, 1990 Diagnostic accuracy and pitfalls of [iodine-131]6-beta-iodomethyl- 19-norcholesterol (NP-59) imaging. J Nucl Med 31: 526-534. (Pubitemid 20144725)
96. Gross MD, Shapiro B, Thrall JH, Freitas JE, Beierwaltes WH, 1984 The scintigraphic imaging of endocrine organs. Endocr Rev 5: 221-281.
97. Bardet S, Rohmer V, Murat A, et al, 1996 131I-6 beta- iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas. Clin Endocrinol (Oxf) 44: 587-596.
98. Imperiale A, Olianti C, Mannelli M, La Cava G, Pupi A, 2005 Tomographic evaluation of [131I] 6beta-iodomethyl- norcholesterol standardised uptake trend in clinically silent monolateral and bilateral adrenocortical incidentalomas. Q J Nucl Med Mol Imaging 49: 287-296. (Pubitemid 41569517)
99. Gross MD, Shapiro B, Francis IR, et al, 1994 Scintigraphic evaluation of clinically silent adrenal masses. J Nucl Med 35: 1145-1152.
100. Barzon L, Zucchetta P, Boscaro M, Marzola MC, Bui F, Fallo F, 2001 Scintigraphic patterns of adrenocortical carcinoma: morpho-functional correlates. Eur J Endocrinol 145: 743-748.
101. Lumachi F, Borsato S, Tregnaghi A, et al, 2007 High risk of malignancy in patients with incidentally discovered adrenal masses: accuracy of adrenal imaging and image-guided fine-needle aspiration cytology. Tumori 93: 269-274. (Pubitemid 47080013)
102. Fujita A, Hyodoh H, Kawamura Y, Kanegae K, Furuse M, Kanazawa K, 2000 Use of fusion images of I-131 meta- iodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med 25: 440-442.
103. van der Harst E, de Herder WW, Bruining HA, et al, 2001 [(123)I]metaiodobenzylguanidine and [(lll)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab 86: 685-693.
104. Cecchin D, Lumachi F, Marzola MC, et al, 2006 A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocr Relat Cancer 13: 525-533. (Pubitemid 43886674)
105. Pacak K, Eisenhofer G, Ahlman H, et al, 2007 International Symposium on Pheochromocytoma. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 3: 92-102.
106. Boland GW, Goldberg MA, Lee MJ, et al, 1995 Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 194: 131-134.
107. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M, 2001 The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 42: 884-892. (Pubitemid 32537435)
108. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A, 2001 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42: 1795-1799. (Pubitemid 34016347)
109. 18F-FDG positron emission tomography scanning. Int J Clin Pract 61: 802-809.
110. Shulkin BL, Wieland DM, Schwaiger M, et al, 1992 PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 33: 1125-1131.
111. Ilias I, Pacak K, 2004 Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89: 479-491. (Pubitemid 38269845)
112. Shapiro B, Gross MD, Shulkin B, 2001 Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 12: 469-475. (Pubitemid 33714249)
113. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS, 20016-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38: 6-8.
114. Timmers HJ, Carrasquillo JA, Whatley M, et al, 2007 Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET. J Nucl Med 48: 1940-1944. (Pubitemid 350232301)
115. Kaji P, Carrasquillo JA, Linehan WM, et al, 2007 The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 156: 483-487. (Pubitemid 46672650)
116. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC, 1999 Pheochromocytomas: imaging with 2- [fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212: 35-41.
117. Hennings J, Lindhe O, Bergström M, Långström B, Sundin A, Hellman P, 2006 [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91: 1410-1414.
118. Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M, 1996 Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med 40: 365-371. (Pubitemid 27089116)
119. Ramachandran B, Houben K, Rozenberg YY, Haigh JR, Varpetian A, Howard BD, 1993 Differential expression of transporters for norepinephrine and glutamate in wild type, variant, and WNT1-expressing PC12 cells. J Biol Chem 268: 23891-23897.
120. Houben K, Dardashti K, Howard BD, 1994 PC12 variants deficient in norepinephrine transporter mRNA have wild type activities of several other related transporters. Neurochem Res 19: 743-751. (Pubitemid 24154240)
121. Newbould EC, Ross GA, Dacie JE, Bouloux PM, Besser GM, Grossman A, 1991 The use of venous catheterization in the diagnosis and localization of bilateral phaeochromocytomas. Clin Endocrinol (Oxf) 35: 55-59.
122. Chew SL, Dacie JE, Reznek RH, et al, 1994 Bilateral phaeochromocytomas in von Hippel-Lindau disease: diagnosis by adrenal vein sampling and catecholamine assay. Q J Med 87: 49-54. (Pubitemid 2035155)
123. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS, 2001 Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134: 315-329. (Pubitemid 32163955)
124. Silverman SG, Mueller PR, Pinkney LP, Koenker RM, Seltzer SE, 1993 Predictive value of image-guided adrenal biopsy: analysis of results of 101 biopsies. Radiology 187: 715-718.
125. Welch TJ, Sheedy PF 2nd, Stephens DH, Johnson CM, Swensen SJ, 1994 Percutaneous adrenal biopsy: review of a 10-year experience. Radiology 193: 341-344.
126. Nórnberg D, 2005 Ultrasound of adrenal gland tumours and indications for fine needle biopsy (uFNB). Ultraschall Med 26: 458-469.
127. Lumachi F, Borsato S, Tregnaghi A, et al, 2003 CT-scan, MRI and image-guided FNA cytology of incidental adrenal masses. Eur J Surg Oncol 29: 689-692. (Pubitemid 37236292)
128. Mody MK, Kazerooni EA, Korobkin M, 1995 Percutaneous CT-guided biopsy of adrenal masses: immediate and delayed complications. J Comput Assist Tomogr 19: 434-439.
129. Voravud N, Shin DM, Dekmezian RH, Dimery I, Lee JS, Hong WK, 1992 Implantation metastasis of carcinoma after percutaneous fine-needle aspiration biopsy. Chest 102: 313-315.
130. Quayle FJ, Spitler JA, Pierce RA, Lairmore TC, Moley JF, Brunt LM, 2007 Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery 142: 497-502.
131. Kocijancic K, Kocijancic I, Guna F, 2004 Role of sonographically guided fine-needle aspiration biopsy of adrenal masses in patients with lung cancer. J Clin Ultrasound 32: 12-16. (Pubitemid 38036680)
132. Dusenbery D, Dekker A, 1996 Needle biopsy of the adrenal gland: retrospective review of 54 cases. Diagn Cytopathol 14: 126-134. (Pubitemid 26104487)
133. Ang TL, Chua TS, Fock KM, Tee AK, Teo EK, Mancer K, 2007 EUS-FNA of the left adrenal gland is safe and useful. Ann Acad Med Singapore 36: 954-957.
134. Jhala NC, Jhala D, Eloubeidi MA, et al, 2004 Endoscopic ultrasound-guided fine-needle aspiration biopsy of the adrenal glands: analysis of 24 patients. Cancer 102: 308-314. (Pubitemid 39369718)
135. Dietrich CF, Wehrmann T, Hoffmann C, Herrmann G, Caspary WF, Seifert H, 1997 Detection of the adrenal glands by endoscopic or transabdominal ultrasound. Endoscopy 29: 859-864. (Pubitemid 28043603)
136. DeWitt J, Alsatie M, LeBlanc J, McHenry L, Sherman S, 2007 Endoscopic ultrasound-guided fine-needle aspiration of left adrenal gland masses. Endoscopy 39: 65-71. (Pubitemid 46403129)
137. Eloubeidi MA, Morgan DE, Cerfolio RJ, Eltoum IA, 2008 Transduodenal EUS-guided FNA of the right adrenal gland. Gastrointest Endosc 67: 522-527.
138. Eloubeidi MA, Seewald S, Tamhane A, et al, 2004 EUS- guided FNA of the left adrenal gland in patients with thoracic or GI malignancies. Gastrointest Endosc 59: 627-633. (Pubitemid 38609690)
139. Linos DA, 2000 Adrenal incidentaloma (Adrenaloma). Hormones (Athens) 2: 12-21.
140. Izaki H, Fukumori T, Takahashi M, et al, 2006 Indications for laparoscopic adrenalectomy for non-functional adrenal tumor with hypertension: usefulness of adrenocortical scintigraphy. Int J Urol 13: 677-681. (Pubitemid 43926753)
141. Cerfolio RJ, Vaughan ED Jr, Brennan TG Jr, Hirvela ER, 1993 Accuracy of computed tomography in predicting adrenal tumor size. Surg Gynecol Obstet 176: 307-309.
142. Guerrieri M, De Sanctis A, Crosta F, et al, 2007 Adrenal incidentaloma: surgical update. J Endocrinol Invest 30: 200-204.
143. Pasqual E, Bacchetti S, Waclaw B, Bertolissi F, Grimaldi F, Cagol PP, 2003 Adrenal incidentalomas: indications for surgery. Chir Ital 55: 29-34.
144. Gittens PR Jr, Solish AF, Trabulsi EJ, 2008 Surgical management of metastatic disease to the adrenal gland. Semin Oncol 35: 172-176.
145. Mercier O, Fadel E, Mussot S, et al, 2007 Is surgery required for patients with isolated adrenal metastasis of non-small cell lung carcinoma? Presse Med 36: 1743-1752.
146. Mittendorf EA, Lim SJ, Schacherer CW, et al, 2008 Melanoma adrenal metastasis: natural history and surgical management. Am J Surg 195: 363-368.
147. Prinz RA, 1995 A comparison of laparoscopic and open adrenalectomies. Arch Surg 130: 489-492.
148. Jossart GH, Burpee SE, Gagner M, 2000 Surgery of the adrenal glands. Endocrinol Metab Clin North Am 29: 57-68.
149. Thompson GB, Grant CS, van Heerden JA, et al, 1997 Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients. Surgery 6: 1132-1136.
150. Winfield HN, Hamilton BD, Bravo EL, Novick AC, 1988 Laparoscopic adrenalectomy: the preferred choice? A comparison to open adrenalectomy. J Urol 160: 325-329.
151. Brunt LM, Doherty GM, Norton JA, Soper NJ, Quasebarth MA, Moley JF, 1996 Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms. J Am Coll Surg 183: 1-10.
152. ZografosGN, Markou A, Ageli C, et al, 2006 Laparoscopic surgery for adrenal tumors. A retrospective analysis. Hormones (Athens) 5: 52-56.
153. Emral R, Uysal AR, Asik M, et al, 2003 Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr J 50: 399-408. (Pubitemid 37129032)
154. Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T, 2001 The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 54: 797-804.
155. Tada K, Okuda Y, Yamashita K, 1988 Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and α-methyl-p-tyrosine to control hypercatecholaminemia. Horm Res 49: 295-297.
156. Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr, 1997 Metyrosine and pheochromocytoma. Arch Intern Med 157: 901-906.
157. Eisenhofer G, Bornstein SR, Brouwers FM, et al, 2004 Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11: 423-436. (Pubitemid 39331275)
158. Rose B, Matthay KK, Price D, et al, 2003 High-dose 131I- metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98: 239-248. (Pubitemid 36828446)
159. Salmenkivi K, Heikkilä P, Haglund C, Arola J, 2004 Malignancy in pheochromocytomas. APMIS 112: 551-559.
160. Ghose RP, Hall PM, Bravo EL, 1999 Medical management of aldosterone-producing adenomas. Ann Intern Med 131: 105-108.
161. Lim PO, Young WF, MacDonald TM, 2001 A review of the medical treatment of primary aldosteronism. J Hypertens 19: 353-361. (Pubitemid 32195369)
162. Young WF Jr, 2003 Primary aldosteronism - treatment options. Growth Horm IGF Res 13 Suppl A: S102-108.
163. Sica DA, 2005 Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10: 23-29.
164. Karagiannis A, Tziomalos K, Papageorgiou A, et al, 2008 Spironolactone versus eplerenone for the treat- ment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 9: 509-515.
165. Haak HR, Hermans J, van de Velde CJ, et al, 1994 Optimal treatment of adrenocortical carcinoma with mitotane: results of a consecutive series of 96 patients. Br J Cancer 69: 947-951. (Pubitemid 24140681)
166. Terzolo M, Angeli A, Fassnacht M, et al, 2007 Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356: 2372-2380.
167. Hermsen IG, Gelderblom H, Kievit J, Romijn JA, Haak HR, 2008 Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur J Endocrinol 158: 911-919. (Pubitemid 351837381)
168. Fassnacht M, Hahner S, Polat B, et al, 2006 Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91: 4501-4504. (Pubitemid 44833430)
169. Xiao YY, Tian JL, Li JK, Yang L, Zhang JS, 2008 CT-guided percutaneous chemical ablation of adrenal neoplasms. Am J Roentgenol 190: 105-110.
170. Kirschner LS, 2006 Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 91: 14-21.
171. Libè R, Dall'Asta C, Barbetta L, Baccarelli A, Beck- Peccoz P, Ambrosi B, 2002 Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 147: 489-494. (Pubitemid 35238144)
172. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M, 1999 Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 84: 520-526. (Pubitemid 29075678)
173. Virkkala A, Välimäki M, Pelkonen R, et al, 1989 Endocrine abnormalities in patients with adrenal tumours incidentally discovered on computed tomography. Acta Endocrinol (Copenh) 121: 67-72. (Pubitemid 19167533)
174. Barry MK, van Heerden JA, Farley DR, Grant CS, Thompson GB, Ilstrup DM, 1998 Can adrenal incidentalomas be safely observed? World J Surg 22: 599-603.
175. Bastounis EA, Karayiannakis AJ, Anapliotou ML, Nakopoulou L, Makri GG, Papalambros EL, 1997 Incidentalomas of the adrenal gland: diagnostic and therapeutic implications. Am Surg 63: 356-360. (Pubitemid 27152723)
176. Sirin J, Tervahartiala P, Sivula A, Haapiainen R, 2000 Natural course of adrenal incidentalomas: seven-year follow-up study. World J Surg 24: 579-582. (Pubitemid 30210849)
177. Kim HY, Kim SG, Lee KW, et al, 2005 Clinical study of adrenal incidentaloma in Korea. Korean J Intern Med 20: 303-309.
178. Grossrubatscher E, Vignati F, Possa M, et al, 2001 The natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation. J Endocrinol Invest 24: 846-855. (Pubitemid 34036714)
179. Tsvetov G, Shimon I, Benbassat C, 2007 Adrenal incidentaloma: clinical characteristics and comparison between patients with and without extraadrenal malignancy. J Endocrinol Invest 30: 647-652. (Pubitemid 350104093)
180. Bülow B, Jansson S, Juhlin C, et al, 2006 Adrenal incidentaloma - follow-up results from a Swedish prospective study. Eur J Endocrinol 154: 419-423.
181. Terzolo M, Osella G, Ali A, et al, 1998 Subclinical Cushing's syndrome in adrenal incidentaloma. Clin Endocrinol (Oxf) 48: 89-97. (Pubitemid 28122438)